Acute respiratory distress syndrome (ARDS)
Supplements studied for acute respiratory distress syndrome (ARDS).
Overview
Three supplements are indexed for acute respiratory distress syndrome (ARDS) across 11 studies, all with low to medium-low ratings.
Inositol (WA 52; low effect size, high evidence, medium trust) was once considered for premature infants, but newer high-quality research found no benefit and possible increased risks of death or serious complications; it is not recommended for infants at risk of ARDS. Gamma-Linolenic Acid (WA 52; low effect size, high evidence, medium trust) has only been studied in combination formulas for severe lung disease, with no clear improvements in survival, ventilator time, or ICU stay.
N-Acetyl Cysteine (NAC) (WA 48; low effect size, medium evidence, medium trust) given intravenously shows mixed results—some studies suggest possible benefit for breathing and survival, others find none—and oral NAC has not been studied for ARDS. Genetic differences may influence response. See the heatmap and evidence reviews below for full trial detail.
Effect graph
Relevant supplements
Relevant supplements sorted by DEX Score.
Studies
Find individual evidence reviews for supplements sorted by DEX Score.
3 supplements for rated at least stars. All purchase bands. No minimum star filter.
Evidence visualised
Same ratings as above, aggregated so you can see coverage and imbalance.